Akeso和INOVIO在2026年后期启动第二阶段试验,利用cadonilimiab和INO-5412测试血浆复合免疫疗法。 Akeso and INOVIO launch a Phase II trial in late 2026 testing a combo immunotherapy for glioblastoma using cadonilimab and INO-5412.

Akeso和INOVIO已发起临床试验,使用Akeso的cadonilimab和INOVIO的DNA疫苗INO-5412,测试对致命脑癌Glioblastoma的混合免疫疗法。 Akeso and INOVIO have launched a clinical trial to test a combination immunotherapy for glioblastoma, a deadly brain cancer, using Akeso’s cadonilimab and INOVIO’s DNA vaccine INO-5412. 由Dana-Farber癌症研究所牵头的第二阶段INSIGHT试验旨在通过封锁两个关键检查点和改善肿瘤的T细胞活动,促进免疫反应。 The Phase II INSIGhT trial, led by Dana-Farber Cancer Institute, aims to boost immune responses by blocking two key checkpoints and improving T cell activity in tumors. 根据以往显示的免疫激活与长期存活有关的结果,审判定于2026年底开始施药。 Building on prior results showing immune activation linked to longer survival, the trial is set to begin dosing in late 2026. 合作旨在扩大对一种疗法很少有效的疾病提供的治疗选择。 The collaboration seeks to expand treatment options for a disease with few effective therapies.